James Sillibourne

Title: The Innovative Contributions of James Sillibourne

Introduction

James Sillibourne is a notable inventor based in London, GB, recognized for his significant contributions to the field of biotechnology. With a total of nine patents to his name, Sillibourne has made strides in developing innovative solutions that address complex biological challenges.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof." This invention provides a chimeric cytokine receptor (CCR) that includes an exodomain binding to a ligand selected from a tumor-secreted factor, a chemokine, and a cell-surface antigen, along with a cytokine receptor endodomain. Another notable patent is the "Nucleic acid construct," which comprises a first nucleotide sequence of interest, a frame-slip motif or a translational readthrough motif, and a second nucleotide sequence of interest. This invention also includes vectors and cells expressing such a construct, along with a method for modulating the relative expression of two transgenes.

Career Highlights

Sillibourne's career is marked by his work at Autolus Limited, a company that focuses on developing innovative T-cell therapies for cancer treatment. His expertise in biotechnology and patent development has positioned him as a key player in the industry.

Collaborations

James Sillibourne has collaborated with notable colleagues, including Martin Pulé and Shaun Cordoba, contributing to the advancement of their shared goals in biotechnology and innovation.

Conclusion

James Sillibourne's inventive spirit and dedication to biotechnology have led to significant advancements in the field. His patents reflect a commitment to addressing critical challenges in medicine and biology.